|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
VALENCIA, SPAIN, Sept. 05, 2018-- via NEWMEDIAWIRE-- Zenosense, Inc., a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the ...
OTC:ZENO Zenosense, Inc. (OTC:ZENO) is a healthcare technology company located in Valencia, Spain. The company’s main focus is a novel hand-held point-of-care (POC) cardiac diagnostic device called MIDS ...
Zenosense, Inc. (OTCQB: ZENO, "Zenosense", the "Company"), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held device for the early detection of heart attack at the Point of Care, is pleased to announce that the Company is now trading on the OTC Markets Group OTCQB “Venture Market”. The OTCQB is recognized as an Established Public Market by the U.S. Securities and Exchange Commission and is a leading market for entrepreneurial and development stage U.S. and international companies.
New York, New York--(Newsfile Corp. - June 28, 2018) - NetworkNewsAudio announces the Audio Press Release (APR) titled "Diagnostics Play Critical Role in Medical Sector," featuring Zenosense (OTC Pink: ZENO). To hear the NetworkNewsAudio version, visit http://nnw.fm/kqyU7To read the original editorial, visit http://nnw.fm/8ZAlrDeveloped by the Company's MIDS Medical Limited joint venture (MML) based at the prestigious Sci-Tech Daresbury campus in the United Kingdom, MIDS Cardiac is a handheld POC technology for the detection of ...
Zenosense, Inc. , a healthcare technology company primarily focused on the development and commercialization of MIDS Cardiac™, a Point of Care handheld device for the early detection of certain cardiac ...